Melanotan II Peptide Research: Comprehensive Scientific Review of MT-II Melanocortin Agonist
Shop Our Top Compounds
Melanotan II Peptide Research: Comprehensive Scientific Review of the MC1R/MC4R Melanocortin Agonist
All information presented in this article is for research and educational purposes only. Melanotan II is sold strictly as a research compound and is not intended for human consumption.
Among the most extensively studied synthetic peptides in modern pharmacology, Melanotan II (MT-II) occupies a unique position at the intersection of dermatology, endocrinology, neuroscience, and reproductive biology. Originally developed at the University of Arizona as a photoprotective agent, melanotan II peptide research has expanded into a remarkably broad scientific landscape — revealing that this single cyclic heptapeptide engages multiple melanocortin receptor subtypes to influence pigmentation, sexual function, appetite regulation, and inflammatory signaling.
This comprehensive review examines the published research surrounding MT-II as a melanocortin agonist, from its structural chemistry and mechanism of action through the diverse physiological pathways it modulates. Drawing on peer-reviewed literature from PubMed, The New England Journal of Medicine, and leading pharmacology journals, this guide provides researchers with an authoritative overview of one of the most pharmacologically versatile alpha-MSH analogs ever synthesized. For a broader understanding of peptide science, explore our Peptide Glossary.
What Is Melanotan II? Origins and Development of the Cyclic Heptapeptide
The University of Arizona Research Program
Melanotan II (MT-II) is a synthetic cyclic lactam heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH), originally designed and synthesized by Dr. Victor Hruby and colleagues at the University of Arizona during the late 1980s and early 1990s. The peptide was developed as part of a broader research initiative aimed at creating a pharmacological agent capable of stimulating melanogenesis — the natural production of melanin pigment in the skin — as a potential strategy for photoprotection against ultraviolet (UV) radiation damage (Hadley & Dorr, 2006).
The development of MT-II emerged from decades of structure-activity relationship (SAR) studies on melanocortin peptides. The foundational work by Al-Obeidi, Hruby, and Hadley demonstrated that constraining the core pharmacophore of α-MSH into a cyclic structure dramatically enhanced potency, receptor binding affinity, and enzymatic stability compared to the native linear hormone (Al-Obeidi et al., 1989).
Chemical Identity and Nomenclature
Melanotan II is formally designated as Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂. It is a non-selective melanocortin receptor agonist with demonstrated activity at MC1R, MC3R, MC4R, and MC5R receptor subtypes. The molecular weight of MT-II is approximately 1024.2 Da, and its molecular formula is C₅₀H₆₉N₁₅O₉.
In published literature, the compound appears under several designations including melanotan 2, MT-II, MTII, and its CAS registry number 121062-08-6. Researchers should note that MT-II is structurally and pharmacologically distinct from Melanotan I (afamelanotide), a linear tridecapeptide that has progressed through a separate clinical development pathway.
The Melanocortin Receptor System: A Primer for MT-II Research
The Five Melanocortin Receptors (MC1R–MC5R)
Understanding melanotan II peptide research requires a thorough grasp of the melanocortin receptor system — a family of five G protein-coupled receptors (GPCRs) designated MC1R through MC5R. Each receptor exhibits distinct tissue distribution patterns and physiological roles:
- MC1R — Expressed primarily on melanocytes in the skin and hair follicles. Mediates pigmentation responses and plays a central role in melanogenesis. Also expressed on immune cells where it modulates inflammatory signaling.
- MC2R — The ACTH receptor, expressed in the adrenal cortex. Exclusively activated by adrenocorticotropic hormone (ACTH) and does not respond to α-MSH or MT-II.
- MC3R — Expressed in the central nervous system (CNS), particularly the hypothalamus, and in peripheral tissues. Involved in energy homeostasis and feeding behavior regulation.
- MC4R — Widely expressed in the CNS, including the hypothalamus, cortex, brainstem, and spinal cord. Critical regulator of appetite, energy expenditure, sexual function, and autonomic nervous system activity.
- MC5R — Found in exocrine glands, adipose tissue, and various peripheral organs. Associated with sebaceous gland function and lipid metabolism.
Endogenous Ligands of the Melanocortin System
The melanocortin receptors are modulated by a sophisticated array of endogenous peptide ligands derived from the precursor protein proopiomelanocortin (POMC). Key endogenous agonists include α-MSH, β-MSH, γ-MSH, and ACTH. The endogenous antagonist agouti-related protein (AgRP) selectively inhibits MC3R and MC4R, providing a counterbalancing mechanism in central energy homeostasis circuits. Agouti signaling protein (ASIP) antagonizes MC1R in the skin, influencing pigmentation patterns.
MT-II acts as a non-selective agonist at MC1R, MC3R, MC4R, and MC5R, mimicking the actions of endogenous melanocortin peptides across multiple receptor subtypes simultaneously. This broad receptor engagement profile explains the compound’s diverse range of pharmacological effects observed in research settings.
Structural Chemistry of Melanotan II: The Cyclic Lactam Advantage
From Linear α-MSH to Cyclic MT-II
Native α-MSH is a linear tridecapeptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂) with relatively low potency and rapid enzymatic degradation in vivo. The critical pharmacophore — the minimal sequence required for melanocortin receptor activation — was identified as the His-Phe-Arg-Trp tetrapeptide motif corresponding to positions 6–9 of α-MSH.
The design of MT-II by the Hruby laboratory incorporated several critical structural modifications that dramatically enhanced its pharmacological profile:
- Norleucine (Nle) substitution at position 4 — replacing the oxidation-prone methionine residue to improve chemical stability.
- D-Phenylalanine (D-Phe) at position 7 — inverting the stereochemistry of the phenylalanine residue to enhance receptor binding affinity and confer resistance to enzymatic proteolysis.
- Lactam bridge cyclization — forming a covalent amide bond between the side chains of Asp⁵ and Lys¹⁰ to constrain the peptide backbone into a cyclic conformation that optimally presents the His-D-Phe-Arg-Trp pharmacophore for receptor engagement.
Structure-Activity Relationships and Receptor Selectivity
Preformulation studies by Ugwu et al. (1994) characterized the physicochemical properties of MT-II, determining the pKa values of the histidine (6.54) and arginine (11.72) residues and establishing an apparent partition coefficient (PC octanol) of 2.82 at physiological pH, suggesting favorable membrane permeability. These foundational studies were critical for understanding the peptide’s pharmacokinetic behavior and informed dosage form development for preclinical research.
The cyclic lactam structure of MT-II confers several pharmacological advantages over linear melanocortin analogs:
- Enhanced potency: MT-II exhibits superpotent melanotropic activity in vitro, orders of magnitude greater than linear α-MSH at stimulating melanocortin receptors.
- Improved metabolic stability: The cyclic conformation provides significant resistance to aminopeptidases and endopeptidases that rapidly degrade linear peptides.
- Extended duration of action: The combination of enhanced stability and strong receptor binding translates to prolonged biological effects in research models.
- Ability to cross the blood-brain barrier (BBB): Unlike larger linear melanocortin peptides, the compact cyclic structure of MT-II enables CNS penetration, facilitating central MC3R and MC4R activation.
For researchers interested in comparing MT-II with other research peptides, explore our catalog including Shop Melanotan II for laboratory investigation.
Melanogenesis Research: MC1R Activation and Photoprotection
The MC1R/cAMP/MITF Signaling Cascade
The most extensively characterized action of melanotan 2 in research settings is its activation of melanocortin 1 receptors (MC1R) on epidermal melanocytes. This pathway represents the primary mechanism through which MT-II stimulates melanogenesis — the biosynthesis of melanin pigment.
Research has demonstrated that upon binding MC1R, MT-II triggers a well-characterized intracellular signaling cascade:
- Gαs protein coupling — MC1R activation stimulates adenylyl cyclase via the stimulatory G-protein alpha subunit.
- cAMP elevation — Intracellular cyclic adenosine monophosphate (cAMP) levels rise, activating protein kinase A (PKA).
- CREB phosphorylation — PKA phosphorylates the cAMP response element-binding protein (CREB) transcription factor.
- MITF upregulation — Phosphorylated CREB drives transcription of microphthalmia-associated transcription factor (MITF), the master regulator of melanocyte differentiation and melanogenesis.
- Melanogenic enzyme induction — MITF upregulates the expression of tyrosinase (TYR), tyrosinase-related protein 1 (TRP-1), and dopachrome tautomerase (TRP-2/DCT), the three key enzymes in melanin biosynthesis.
- Eumelanin production — The activated enzymatic machinery converts L-tyrosine through L-DOPA and dopaquinone intermediates to eumelanin, the brown-black pigment that provides the most effective UV photoprotection.
Eumelanin vs. Pheomelanin: The Photoprotective Ratio
A critical distinction in melanogenesis research is between eumelanin (photoprotective brown-black pigment) and pheomelanin (photosensitizing red-yellow pigment). Research has demonstrated that MC1R activation preferentially stimulates eumelanin synthesis, shifting the eumelanin-to-pheomelanin ratio favorably. This is particularly significant because pheomelanin can generate reactive oxygen species (ROS) upon UV exposure, potentially contributing to DNA damage.
Phase I Tanning Studies
The landmark phase I clinical study by Dorr et al. (1996) provided the first human evidence that MT-II possesses tanning activity. In this single-blind, placebo-controlled trial conducted in three normal male volunteers, subcutaneous administration of MT-II at doses ranging from 0.01 to 0.03 mg/kg produced measurable increases in skin pigmentation as assessed by quantitative reflectance spectroscopy. Notably, tanning was observed in the face, upper body, and buttock regions after only five alternating-day doses. A subsequent study by Dorr et al. (2004) further demonstrated that MT-II administered in combination with solar UV radiation enhanced tanning responses in human volunteers, establishing the compound’s melanogenic efficacy under conditions more closely mimicking natural sun exposure.
These findings established proof-of-concept that pharmacological activation of the melanocortin system could stimulate protective melanogenesis in human skin, supporting the original research hypothesis behind MT-II’s development. To explore related research compounds, visit Shop BPC-157 and other peptides in our catalog.
Sexual Function Research: MC4R-Mediated Pathways and the Path to Bremelanotide
Discovery of Erectogenic Properties
One of the most significant and unexpected findings in melanotan II peptide research was the observation of penile erections as a side effect during the original tanning studies. During the 1996 phase I trial, researchers documented a “stretching and yawning complex” correlated with the onset of spontaneous penile erections lasting 1–5 hours following MT-II administration (Dorr et al., 1996). This serendipitous discovery redirected a significant branch of melanocortin research toward understanding the role of central MC4R activation in sexual function.
Double-Blind Clinical Studies
Wessells et al. (1998) conducted the first dedicated investigation into MT-II’s erectogenic properties in a double-blind, placebo-controlled crossover study involving men with psychogenic erectile dysfunction. Subcutaneous administration of MT-II at a dose of 0.025 mg/kg initiated clinically significant erections as measured by RigiScan monitoring, with subjects experiencing a mean of 41 minutes of tip rigidity greater than 80%.
A subsequent expanded study by Wessells et al. (2000) administered MT-II to 20 men with both psychogenic and organic erectile dysfunction. In the absence of visual sexual stimulation, MT-II induced penile erection in 17 of 20 subjects (85%). Increased sexual desire was reported following 68% of MT-II doses compared to only 19% of placebo doses (P<0.01), establishing that the compound’s effects extended beyond simple erectile function to encompass central arousal and sexual motivation pathways.
Mechanism: Central MC4R Activation
Research has established that the sexual function effects of MT-II are mediated primarily through MC4R activation in the central nervous system, distinct from the peripheral MC1R-mediated pigmentation effects. Molinoff et al. (2003) demonstrated that systemic administration of the MT-II-derived compound PT-141 (bremelanotide) activated neurons in the hypothalamic paraventricular nucleus (PVN) as shown by increased c-Fos immunoreactivity — the same CNS region containing neurons that project to the spinal cord circuits controlling erectile tissue.
This central mechanism of action represented a fundamentally different approach to addressing erectile function compared to peripheral vasodilators, as it acted on the brain’s arousal circuits rather than directly on penile vascular smooth muscle.
Development of Bremelanotide (PT-141)
The erectogenic findings with MT-II led directly to the development of bremelanotide (PT-141), a metabolite and structural derivative of MT-II. Diamond et al. (2004) demonstrated in a double-blind, placebo-controlled study that intranasal PT-141 produced rapid, dose-dependent increases in erectile activity in both healthy males and patients with mild-to-moderate erectile dysfunction. Bremelanotide subsequently completed pivotal Phase III clinical trials and received FDA approval in 2019 under the brand name Vyleesi® for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women — representing the first FDA-approved melanocortin receptor agonist for sexual dysfunction and a direct clinical translation of the original melanotan II research program.
Appetite, Energy Homeostasis, and Body Composition Research
MC4R in the Hypothalamic Feeding Circuit
Beyond pigmentation and sexual function, melanotan 2 has been extensively studied for its effects on appetite regulation and energy homeostasis through central MC3R and MC4R activation. The melanocortin-4 receptor is recognized as one of the most critical nodes in hypothalamic energy balance circuits, with loss-of-function MC4R mutations representing the most common monogenic cause of severe early-onset obesity in humans (Fatima et al., 2022).
Within the arcuate nucleus of the hypothalamus, two opposing neuronal populations regulate feeding behavior:
- POMC/CART neurons — produce α-MSH and other melanocortin peptides that activate MC4R to suppress appetite and increase energy expenditure.
- NPY/AgRP neurons — produce neuropeptide Y (NPY) and agouti-related protein (AgRP) that stimulate feeding behavior and antagonize MC4R signaling.
MT-II, as a potent MC3R/MC4R agonist, mimics the anorexigenic (appetite-suppressing) actions of endogenous melanocortins in this circuit.
Preclinical Feeding and Adiposity Studies
Research by Pierroz et al. (2002) demonstrated that chronic central infusion of MT-II (15 nmol/day for 7 days) in Sprague-Dawley rats produced near-complete anorexia for 1–2 days, followed by a gradual return of feeding despite continued administration — suggesting an escape or desensitization phenomenon. Critically, even after feeding normalized, MT-II-treated animals exhibited a two-fold reduction in fat pad weight compared to pair-fed controls, indicating sustained effects on energy metabolism and adiposity that extended beyond simple appetite suppression.
When co-administered with the orexigenic neuropeptide Y, MT-II canceled the NPY-driven hyperphagia and dramatically curtailed the NPY-induced increases in fat pad weight, serum insulin, and leptin levels. These findings established that melanocortin signaling and NPY pathways interact antagonistically in the control of feeding and metabolism.
Côté et al. (2017) extended these observations, demonstrating that activation of the central melanocortin system through chronic MT-II treatment produced sustained reductions in body mass without requiring long-term caloric restriction. This research suggested that melanocortin agonism may reduce body weight through mechanisms including increased energy expenditure and altered substrate metabolism, rather than solely through appetite suppression.
Anti-Inflammatory Properties of Melanocortin Signaling
Melanocortins as Inflammation Resolvers
An expanding body of research has established that the melanocortin system — and by extension, melanocortin agonists like MT-II — participates in the resolution of inflammatory responses. Research has demonstrated that α-MSH and synthetic melanocortin agonists exert potent anti-inflammatory effects through multiple mechanisms (Catania et al., 2004):
- NF-κB pathway inhibition — Melanocortin receptor activation has been shown to suppress nuclear factor kappa-B (NF-κB) DNA-binding activity, reducing transcription of pro-inflammatory genes including TNF-α, IL-1β, IL-6, and IL-8.
- Anti-inflammatory cytokine induction — MC receptor activation promotes production of anti-inflammatory mediators including IL-10.
- Immune cell modulation — Melanocortins modulate macrophage, neutrophil, and lymphocyte function, promoting resolution of inflammatory responses rather than propagation.
- Neuroprotective signaling — Central melanocortin receptor activation has demonstrated neuroprotective effects in models of neuroinflammation, potentially mediated through MC4R in brain-resident immune cells.
These anti-inflammatory properties are mediated through MC1R on peripheral immune cells and MC3R/MC4R in the central nervous system. Because MT-II activates all of these receptor subtypes, it serves as a valuable research tool for investigating the broad anti-inflammatory potential of melanocortin system activation.
The anti-inflammatory axis of melanocortin research has generated significant interest in conditions characterized by chronic inflammation, with ongoing research exploring the therapeutic potential of selective melanocortin receptor agonists in inflammatory and autoimmune disease models.
Melanotan II vs. Melanotan I (Afamelanotide): A Comparative Analysis
Structural and Pharmacological Differences
Researchers frequently encounter confusion between Melanotan I (afamelanotide) and Melanotan II — two compounds that share a common developmental origin but possess fundamentally different pharmacological profiles:
| Feature | Melanotan I (Afamelanotide) | Melanotan II (MT-II) |
|---|---|---|
| Structure | Linear tridecapeptide (13 amino acids) | Cyclic lactam heptapeptide (7 amino acids) |
| Sequence | [Nle⁴, D-Phe⁷]-α-MSH | Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ |
| Receptor Selectivity | Relatively MC1R-preferring | Non-selective (MC1R, MC3R, MC4R, MC5R) |
| BBB Penetration | Limited | Crosses the blood-brain barrier |
| Primary Research Focus | Skin pigmentation, photoprotection | Pigmentation, sexual function, appetite, inflammation |
| Clinical Development | FDA-approved (Scenesse®) for EPP | Research compound; derivative PT-141 approved |
Divergent Clinical Pathways
Afamelanotide (Melanotan I) followed a focused clinical development path targeting MC1R-mediated pigmentation, ultimately gaining FDA approval in 2019 as Scenesse® for the treatment of erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe phototoxicity. The pivotal Phase III trial by Langendonk et al. (2015), published in The New England Journal of Medicine, demonstrated that afamelanotide significantly increased the duration of time patients could spend in sunlight without experiencing phototoxic reactions.
MT-II, by contrast, did not pursue a focused regulatory pathway for pigmentation. Instead, its non-selective receptor profile led research to branch into multiple therapeutic areas, with the most clinically successful translation being the development of bremelanotide (PT-141) for sexual dysfunction. The broader receptor engagement of MT-II has made it an invaluable research tool for investigating the melanocortin system as a whole but also introduced complexity in terms of potential off-target effects across receptor subtypes.
For researchers exploring comparative peptide analysis, visit our BPC-157 Complete Guide for insights into another extensively studied research peptide.
Research Studies and Peer-Reviewed Citations
The following peer-reviewed studies represent the foundational and most significant publications in melanotan II peptide research:
Al-Obeidi F, Hadley ME, Pettitt BM, Hruby VJ. “Design of a new class of superpotent cyclic α-melanotropins based on quenched dynamic simulations.” Journal of the American Chemical Society, 111(9), 3413–3416, 1989. DOI: 10.1021/ja00191a044
Ugwu SO, Blanchard J, Dorr RT, Levine N, Brooks C, Hadley ME, Aickin M, Hruby VJ. “Preformulation studies with melanotan-II: a potential skin cancer chemopreventive agent.” Journal of Pharmaceutical Sciences, 83(8), 1081–1086, 1994. DOI: 10.1002/jps.2600830805
Dorr RT, Lines R, Levine N, Brooks C, Xiang L, Hruby VJ, Hadley ME. “Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.” Life Sciences, 58(20), 1777–1784, 1996. DOI: 10.1016/0024-3205(96)00160-9
Wessells H, Fuciarelli K, Hansen J, Hadley ME, Hruby VJ, Dorr R, Levine N. “Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study.” Journal of Urology, 160(2), 389–393, 1998. PMID: 9679884
Wessells H, Levine N, Hadley ME, Dorr R, Hruby VJ. “Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II.” International Journal of Impotence Research, 12(Suppl 4), S74–S79, 2000. DOI: 10.1038/sj.ijir.3900582
Pierroz DD, Ziotopoulou M, Ungsunan L, Moschos S, Flier JS, Mantzoros CS. “The melanocortin agonist Melanotan-II reduces the orexigenic and adipogenic effects of neuropeptide Y (NPY) but does not affect the NPY-driven suppressive effects on the gonadotropic and somatotropic axes.” Journal of Neuroendocrinology, 14(12), 969–975, 2002. DOI: 10.1046/j.1365-2826.2002.00862.x
Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. “PT-141: a melanocortin agonist for the treatment of sexual dysfunction.” Annals of the New York Academy of Sciences, 994, 96–102, 2003. DOI: 10.1111/j.1749-6632.2003.tb03167.x
Catania A, Gatti S, Colombo G, Lipton JM. “Targeting melanocortin receptors as a novel strategy to control inflammation.” Pharmacological Reviews, 56(1), 1–29, 2004. DOI: 10.1124/pr.56.1.1
Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. “Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.” International Journal of Impotence Research, 16(1), 51–59, 2004. DOI: 10.1038/sj.ijir.3901139
Dorr RT, Ertl G, Levine N, Brooks C, Bangert JL, Powell MB, Humphrey S, Alberts DS. “Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers.” Archives of Dermatology, 140(7), 827–835, 2004. DOI: 10.1001/archderm.140.7.827
Hadley ME, Dorr RT. “Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.” Peptides, 27(4), 921–930, 2006. DOI: 10.1016/j.peptides.2005.01.029
Langendonk JG, Balwani M, Anderson KE, Bonkovsky HL, Anstey AV, Bissell DM, Bloomer J, Edwards C, Neber R, Parker C, Phillips JD, Lim HW, Hamzavi I, Deybach JC, Kauppinen R, Rhodes LE, Frank J, Murphy GM, Karstens FPJ, Sijbrands EJG, de Rooij FWM, Lebwohl M, Naik H, Goding CR, Wilson JHP, Desnick RJ. “Afamelanotide for erythropoietic protoporphyria.” New England Journal of Medicine, 373(1), 48–59, 2015. DOI: 10.1056/NEJMoa1411481
Côté I, Sakarya Y, Kirichenko N, Morgan D, Carter CS, Tümer N, Scarpace PJ. “Activation of the central melanocortin system chronically reduces body mass without the necessity of long-term caloric restriction.” Canadian Journal of Physiology and Pharmacology, 95(2), 206–214, 2017. DOI: 10.1139/cjpp-2016-0290
Fatima MT, Ahmed I, Fakhro KA, Akil ASA. “Melanocortin-4 receptor complexity in energy homeostasis, obesity and drug development strategies.” Diabetes, Obesity and Metabolism, 24(4), 583–598, 2022. DOI: 10.1111/dom.14618
Frequently Asked Questions About Melanotan II Research
What is Melanotan II and how was it developed?
Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH), originally designed by Dr. Victor Hruby and colleagues at the University of Arizona. It was developed through rational drug design using structure-activity relationship studies to create a constrained, cyclic version of the α-MSH pharmacophore with enhanced potency, metabolic stability, and receptor binding affinity compared to the native linear hormone. MT-II is available for research purposes only and is not approved for human consumption.
How does Melanotan II differ from Melanotan I (afamelanotide)?
While both compounds originated from α-MSH research at the University of Arizona, they differ significantly in structure and pharmacology. Melanotan I (afamelanotide) is a linear tridecapeptide with relative MC1R selectivity, primarily affecting skin pigmentation. Melanotan II is a shorter, cyclic heptapeptide that non-selectively activates MC1R, MC3R, MC4R, and MC5R, producing effects across multiple physiological systems including pigmentation, central nervous system pathways, appetite regulation, and inflammatory signaling. Afamelanotide has received FDA approval for erythropoietic protoporphyria, while MT-II remains a research compound.
What melanocortin receptors does MT-II activate?
MT-II is a non-selective melanocortin receptor agonist that activates MC1R (pigmentation), MC3R (energy homeostasis), MC4R (appetite, sexual function, autonomic regulation), and MC5R (exocrine function). It does not significantly activate MC2R, which is the ACTH-specific adrenal receptor. This broad receptor engagement profile is responsible for the diverse range of pharmacological effects observed in published research.
What is the relationship between Melanotan II and bremelanotide (PT-141)?
Bremelanotide (PT-141) is a metabolite and structural analog of Melanotan II that was developed specifically for investigating melanocortin-mediated sexual function. PT-141 is the carboxylated derivative of MT-II, created by removing the N-terminal acetyl group. Research on MT-II’s unexpected erectogenic effects led directly to the development of PT-141, which completed clinical trials and received FDA approval in 2019 as Vyleesi® for hypoactive sexual desire disorder in premenopausal women.
What role does MT-II play in melanogenesis research?
In melanogenesis research, MT-II serves as a potent pharmacological tool for activating the MC1R/cAMP/PKA/MITF signaling cascade in melanocytes. Research has demonstrated that this activation upregulates tyrosinase and related enzymes, preferentially stimulating eumelanin (brown-black, photoprotective pigment) synthesis over pheomelanin (red-yellow, potentially photosensitizing pigment). Phase I clinical studies confirmed that MT-II administration increased measurable skin pigmentation in human subjects.
How does MT-II influence appetite and body composition in research models?
Published studies have demonstrated that MT-II, acting through central MC3R and MC4R in the hypothalamus, produces potent anorexigenic effects and reduces adiposity in animal models. In rodent research, central administration of MT-II reduced fat pad weight by approximately 50% compared to pair-fed controls and counteracted the orexigenic and adipogenic effects of neuropeptide Y. These effects appear to involve both appetite suppression and increased energy expenditure, though tolerance to the anorexigenic effects develops with chronic administration.
What are the anti-inflammatory properties associated with melanocortin agonism?
Research has established that melanocortin receptor activation suppresses NF-κB-mediated transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), promotes anti-inflammatory cytokine production (IL-10), and modulates immune cell function. These effects are mediated through MC1R on peripheral immune cells and MC3R/MC4R in the central nervous system. MT-II’s non-selective agonism at these receptors makes it a useful research tool for investigating the broad anti-inflammatory potential of the melanocortin system.
Is Melanotan II approved for clinical use?
No. Melanotan II is not approved by the FDA, EMA, or any other regulatory authority for clinical use in humans. It is classified as a research chemical and is available for laboratory and investigational purposes only. Its derivative bremelanotide (PT-141) and the related compound afamelanotide (Melanotan I) have each achieved regulatory approval for specific clinical indications through formal drug development pathways.
Conclusion: The Expanding Frontier of Melanotan II Peptide Research
Melanotan II peptide research represents one of the most compelling case studies in modern peptide pharmacology — a single cyclic heptapeptide that, through its non-selective engagement of the melanocortin receptor system, has illuminated fundamental biological pathways spanning pigmentation, sexual function, energy homeostasis, and inflammation. From the original structure-activity relationship studies by Hruby and colleagues through landmark clinical trials demonstrating tanning and erectogenic activity, MT-II has proven to be both a versatile research tool and a platform for translational drug development.
The clinical success of bremelanotide as a direct descendant of MT-II research validates the melanocortin system as a druggable target, while the FDA approval of afamelanotide confirms the therapeutic potential of melanocortin-mediated pigmentation. Meanwhile, ongoing research into MC4R’s role in obesity, MC1R’s contribution to immune regulation, and the broader anti-inflammatory properties of the melanocortin system continues to expand the scientific significance of this peptide family.
For researchers seeking to advance their investigations into melanocortin biology, Iron Peak Peptides provides premium-quality research compounds including Shop Melanotan II and a comprehensive catalog of peptides for laboratory use. Explore our full selection of research peptides and consult our Peptide Glossary for additional scientific context.
Research Disclaimer
The information provided in this article is intended for educational and research purposes only. Melanotan II is a research peptide sold exclusively for in vitro laboratory research and scientific investigation. It is not intended for human consumption, therapeutic use, or as a dietary supplement.
Iron Peak Peptides does not condone or promote the use of any research compound outside of legitimate scientific research. The studies cited herein are presented for informational purposes to support the academic and scientific community. Researchers are responsible for ensuring compliance with all applicable local, state, and federal regulations governing the purchase and use of research chemicals.
This content has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. For research purposes only.
🔬 Explore Research Peptides
- Semax 10mg — $50.00
- 5-Amino-1MQ 50mg (25 Tablets) — $85.00
- HGH (Somatropin) — $90.00
- Epithalon 50mg — $125.00
